Silo Pharma, Inc. (SILO): Entry into a Material Definitive Agreement
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 1, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Norsight Consulting Inc., an Arkansas corporation (the “Seller”). Pursuant to the Agreement, the Seller agre
How this was made
The 30-second read
Why it matters
The transaction introduces new equity potential and may modestly affect share price due to dilution risk.
Market read
Primary corporate action for a micro‑cap; modest trading relevance.
What to watch
Lock‑up provisions and anti‑dilution caps may limit immediate share supply.
Background
Silo Pharma announced a definitive asset purchase agreement with Norsight Consulting, including a cashless warrant for up to 300,000 shares.
Ticker impact
Silo Pharma filed an 8‑K reporting an asset purchase agreement and issuance of a warrant for up to 300,000 shares.
possible modest pressure as the market prices in dilution from the warrant issuance
The agreement is a primary disclosure but involves a small micro‑cap; impact is limited to dilution concerns.
Market effects
Limited to biotech/pharma M&A activity; no broader sector shift.
U.S. micro‑cap market only.
Low
Counterpoint
The warrant could provide upside if the acquired assets generate significant value, offsetting dilution concerns.
Key entities
- companySilo Pharma, Inc.
Issuer of the warrant and purchaser of assets.
- companyNorsight Consulting Inc.
Seller receiving the warrant and shares.
